MENSIA Technologies Receives €3.6 Million from the EU to Develop NEWROFEED, a Non-Invasive, Non-Drug Solution for the Treatment of ADHD in Children

(Attention Deficit Disorder with or without Hyperactivity)

PARIS & RENNES, France–(BUSINESS WIRE)–MENSIA Technologies, a company developing non-invasive medical
devices for the care of the Central Nervous System, announced today that
it has been awarded €3.6 million from the EU as part of the H2020/SME
 call for projects, for its project NEWROFEED. The
objective is to develop an original and non-invasive therapeutic medical
device for children with ADHD.

Developed in close collaboration with neuroscientists and clinicians,
the personalized medical solution NEWROFEED is based on neurofeedback
training of the brain. It is used at home under medical supervision to:

  • Identify and quantify in real time abnormal brain activity in ADHD
  • Personalize treatment with a care protocol adapted to each child;
  • Re-train the patients’ brain wave pattern for lasting normalization;
  • Monitor daily the child’s observance and progress during the programme.

Providing care in a familiar environment promotes the family’s
involvement and hence the child’s willingness to comply with the

Jean-Yves Quentel, CEO of MENSIA Technologies said, « We are
proud that our technology was selected for the EU programme Horizon
2020, one of the most selective programmes funding disruptive
technological innovations. We will therefore accelerate the development
of our medical device NEWROFEED: to demonstrate its efficacy, we will
launch in 2016 a pan-European multicentre clinical study. Our
alternative, non-invasive, non-drug treatment satisfies a major need in
the etiological treatment of ADHD. »

Neurofeedback is a brain training technique usually applied to
the treatment of various disorders (ADHD, addictions, anxiety, etc.), to
help regulate the electrical activity in the brain evidenced by
electroencephalography (EEG). The technique is based on « serious games
» which provide visual or auditory feedback of the brain activity in
real time. During these games, the children are rewarded when they
manage to alter positively their brain wave pattern, which stimulates
their commitment. This physiological treatment induces lasting changes
in the brain with positive long-term effects.
(Monastra V.J
2002, Fuchs T 2003, Duric NS 2012, Meisel V 2014).

ADHD, a major public health issue
is a chronic and incapacitating syndrome, which affects the family,
social and school life of young patients, and has major implications on
their future adult life. It is characterised by persistent symptoms of
inattention, impulsivity and hyperactivity, which may have disabling
repercussions on the child’s daily activities. It is one of the most
common mental disorders in children, but also one of the most neglected.
It is underdiagnosed and poorly managed with drug treatments, not very
effective and often associated with adverse effects.
affects over 5% of children worldwide (Haute Autorité de Santé,
December 2014
), representing a drug market estimated at $9 billion
in 2015.

The technological platform of MENSIA

The core of the technological innovation is
the software suite NeuroRTtm, designed for the development of
applications used for real-time monitoring and analysis of brain signals
generated by electroencephalography (EEG). Based on the OpenViBE
software developed by Inria in close collaboration with experts in
neuroinformatics and clinical neurologists, NeuroRTtm is designed to
develop applications performing a complete brain analysis cycle, from
the acquisition of physiological data to the feedback given to the user.
This platform is based on the latest technological breakthroughs in
signal processing, applied mathematics, automatic learning and
neurosciences. The applications developed with NeuroRT™ are already used
in research laboratories to improve our understanding of the human
brain, or in a clinical setting, as is the case with the NEWROFEED
NeuroRT™ could also provide a non-invasive solution to
treat conditions such as depression, post-stroke movement disorders and

Horizon 2020:

About MENSIA Technologies
in 2012, based in Paris at the international brain and spinal cord
research centre ICM and in Rennes, MENSIA Technologies designs and
develops non-invasive and non-drug medical devices for the treatment of
certain brain disorders.


MENSIA Technologies

Loyer, 01 44 71 00 12 / 06 88 20 35 59